Home
IVVD
IVVD News

Latest Invivyd Inc. (IVVD) News on May 10, 2025

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

GlobeNewswire

2 days ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

What's Going On With Invivyd Stock On Monday?

Benzinga

18 days ago

What's Going On With Invivyd Stock On Monday?

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

GlobeNewswire

19 days ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

GlobeNewswire

a month ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire

2 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

Zacks

2 months ago

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

GlobeNewswire

2 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Simply Wall St.

2 months ago

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025

Insider Monkey

2 months ago

Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025

Adagio Medical cuts workforce and pauses cryo catheter launch in EU

Medical Device Network

2 months ago

Adagio Medical cuts workforce and pauses cryo catheter launch in EU

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine

Zacks

2 months ago

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine

MT Newswires

3 months ago

Sector Update: Health Care Stocks Gain Monday Afternoon

5 Stocks That More Than Doubled Halfway Through Q1

Zacks

3 months ago

5 Stocks That More Than Doubled Halfway Through Q1

MT Newswires

3 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

GlobeNewswire

3 months ago

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Insider Monkey

3 months ago

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

GlobeNewswire

3 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Exploring High Growth Tech Stocks in the United States

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks in the United States

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

GlobeNewswire

3 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

MT Newswires

3 months ago

Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative

Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025

Insider Monkey

3 months ago

Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

GlobeNewswire

3 months ago

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

GlobeNewswire

3 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon

Simply Wall St.

3 months ago

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

GlobeNewswire

3 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

Benzinga

4 months ago

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

GlobeNewswire

4 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?

Insider Monkey

4 months ago

Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?

Adagio Medical announces Todd Usen as new CEO and director

Medical Device Network

5 months ago

Adagio Medical announces Todd Usen as new CEO and director

MT Newswires

5 months ago

Adagio Medical Appoints Todd Usen as CEO

Thomson Reuters StreetEvents

6 months ago

Q3 2024 Invivyd Inc Earnings Call

GuruFocus.com

6 months ago

Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Zacks

6 months ago

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

6 months ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

GlobeNewswire

6 months ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect

GuruFocus.com

6 months ago

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

GlobeNewswire

6 months ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

GlobeNewswire

6 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

GlobeNewswire

6 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

MT Newswires

6 months ago

Invivyd Shares Fall After Revenue Guidance Withdrawal

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

GlobeNewswire

6 months ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

GlobeNewswire

6 months ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

GlobeNewswire

7 months ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

GlobeNewswire

7 months ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

MT Newswires

8 months ago

Invivyd Provides Virology Data Supporting Pemivibart's Effectiveness Against Current SARS-CoV-2 Variants

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

GlobeNewswire

8 months ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Simply Wall St.

8 months ago

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

GlobeNewswire

8 months ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Invivyd to Participate in Upcoming Investor Conferences

GlobeNewswire

8 months ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

GlobeNewswire

8 months ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

GlobeNewswire

8 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

MT Newswires

8 months ago

Invivyd's Covid-19 Antibody Shows 84% Risk Reduction in Phase 3 Trial; Shares Fall

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

GlobeNewswire

8 months ago

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Thomson Reuters StreetEvents

9 months ago

Q2 2024 Invivyd Inc Earnings Call

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Zacks

9 months ago

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

9 months ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

9 months ago

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

MT Newswires

10 months ago

Invivyd Joining Russell 2000, 3000 Indexes

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

GlobeNewswire

10 months ago

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future

Simply Wall St.

10 months ago

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

GlobeNewswire

a year ago

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Invivyd to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Invivyd to Participate at the Jefferies Global Healthcare Conference

MT Newswires

a year ago

Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

GlobeNewswire

a year ago

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

GlobeNewswire

a year ago

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

GlobeNewswire

a year ago

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire

a year ago

Invivyd Elects Two New Independent Members to its Board of Directors

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire

a year ago

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript

With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest

Simply Wall St.

a year ago

With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest

GuruFocus.com

a year ago

Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

a year ago

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

GlobeNewswire

a year ago

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

a year ago

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

GlobeNewswire

a year ago

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

GlobeNewswire

a year ago

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Invivyd Announces CEO Transition

GlobeNewswire

a year ago

Invivyd Announces CEO Transition

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Simply Wall St.

a year ago

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

GlobeNewswire

a year ago

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire

a year ago

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

GlobeNewswire

a year ago

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

GlobeNewswire

a year ago

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Best Value Stocks to Buy for February 1st

Zacks

a year ago

Best Value Stocks to Buy for February 1st

Senate tells social media CEOs they have 'blood on their hands' for failing to protect children

Engadget

a year ago

Senate tells social media CEOs they have 'blood on their hands' for failing to protect children

3 Groundbreaking Biotech Stocks to Invest in Now

InvestorPlace

a year ago

3 Groundbreaking Biotech Stocks to Invest in Now

GlobeNewswire

a year ago

Simplicity Group Unveils WeDYOR: Transforming Due Diligence for Crypto Investments

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

GlobeNewswire

a year ago

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

Is There An Opportunity With Metals Acquisition Limited's (NYSE:MTAL) 35% Undervaluation?

Simply Wall St.

a year ago

Is There An Opportunity With Metals Acquisition Limited's (NYSE:MTAL) 35% Undervaluation?

Virtu Financial Inc (VIRT) Reports Mixed Fourth Quarter and Full Year 2023 Results

GuruFocus.com

a year ago

Virtu Financial Inc (VIRT) Reports Mixed Fourth Quarter and Full Year 2023 Results

Eagle Bancorp Inc (EGBN) Reports Q4 2023 Earnings: Net Income Declines to $20.2 Million

GuruFocus.com

a year ago

Eagle Bancorp Inc (EGBN) Reports Q4 2023 Earnings: Net Income Declines to $20.2 Million

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results

Business Wire

a year ago

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results

Alexander & Baldwin Announces Fourth Quarter and Full-Year 2023 Earnings Release and Conference Call Date

PR Newswire

a year ago

Alexander & Baldwin Announces Fourth Quarter and Full-Year 2023 Earnings Release and Conference Call Date

3 Lithium Stocks to Turn $10,000 Into $1 Million: January 2024

InvestorPlace

a year ago

3 Lithium Stocks to Turn $10,000 Into $1 Million: January 2024

Lithium Americas Stock (NYSE:LAC): Positioned to Profit from an EV Boom

TipRanks

a year ago

Lithium Americas Stock (NYSE:LAC): Positioned to Profit from an EV Boom

15 Small-Cap Stocks with High Potential

Insider Monkey

a year ago

15 Small-Cap Stocks with High Potential

Northwest Bancshares (NWBI) Matches Q4 Earnings Estimates

Zacks

a year ago

Northwest Bancshares (NWBI) Matches Q4 Earnings Estimates

Share on Social Networks: